A model predictive control based scheduling method for HIV therapy. (English) Zbl 1445.92158
Summary: Recently developed models of the interaction of the human immune system and the human immunodeficiency virus (HIV) suggest the possibility of using interruptions of highly active anti-retroviral therapy (HAART) to simulate a therapeutic vaccine and induce cytotoxic lymphocyte (CTL) mediated control of HIV infection. We have developed a model predictive control (MPC) based method for determining optimal treatment interruption schedules for this purpose. This method provides a clinically implementable framework for calculating interruption schedules that are robust to errors due to measurement and patient variations. In this paper, we discuss the medical motivation for this work, introduce the MPC-based method, show simulation results, and discuss future work necessary to implement the method.
MSC:
| 92C60 | Medical epidemiology |
| 93B45 | Model predictive control |
| 93C95 | Application models in control theory |
References:
| [1] | Abbas, U. L.; Mellors, J. W., Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward, Proc. Natl Acad. Sci. USA, 99, 21, 13377-13378 (2002) |
| [2] | Altes, H.; Wodarz, D.; Jansen, V., The dual role of CD4 T helper cells in the infection dynamics of HIV and their importance for vaccination, J. Theor. Biol., 214, 4, 633-646 (2002) |
| [3] | Altfeld, M.; Rosenberg, E.; Shankarappa, R.; Mukherjee, J.; Hecht, F.; Eldridge, R.; Addo, M.; Poon, S.; Phillips, M.; Robbins, G.; Sax, P.; Boswell, S.; Kahn, J.; Brander, C.; Goulder, P.; Levy, J.; Mullins, J.; Walker, B., Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection, J. Exp. Med., 193, 2, 169-180 (2001) |
| [4] | Altfeld, M.; Allen, T.; Yu, X.; Johnston, M.; Agrawal, D.; Korber, B.; Montefiori, D.; O’Connor, D.; Davis, B.; Lee, P.; Maier, E.; Harlow, J.; Goulder, P.; Brander, C.; Rosenberg, E.; Walker, B., HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus, Nature, 420, 6914, 434-439 (2002) |
| [5] | Altfeld, M.; Lunzen, J. V.; Frahm, N.; Yu, X.; Schneider, C.; Eldridge, R.; Feeney, M.; Meyer-Olson, D.; Stellbrink, H.; Walker, B., Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV1 infection, J. Clin. Invest., 109, 6, 837-843 (2002) |
| [6] | Ananworanich, J.; Nuesch, R.; Braz, M. L.; Chetchotisakd, P.; Vibhagool, A.; Wicharuk, S.; Ruxrungtham, K.; Furrer, H.; Cooper, D.; Hirschel, B.; Bernasconi, E.; Cavassini, M.; Ebnöther, C.; Fagard, C.; Genné, D.; Khanna, N.; Perrin, L.; Phanupak, P.; Ubolyam, S.; Vernazza, P.; Yerly, S.; Study, S. H.C., Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial, AIDS, 17, 15, F33-F37 (2003) |
| [7] | Appay, V.; Papagno, L.; Spina, C.; Hansasuta, P.; King, A.; Jones, L.; Ogg, G.; Little, S.; McMichael, A.; Richman, D.; Rowland-Jones, S., Dynamics of T cell responses in HIV infection, J. Immunol., 168, 7, 3660-3666 (2002) |
| [8] | Arnaout, R.; Nowak, M.; Wodarz, D., HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?, Proc. R. Soc. Lond. B Biol. Sci., 267, 1450, 1347-1354 (2000) |
| [9] | Autran, B.; Carcelain, G., AIDS. Boosting immunity to HIV—can the virus help?, Science, 290, 5493, 946-949 (2000) |
| [10] | Betts, M.; Ambrozak, D.; Douek, D.; Bonhoeffer, S.; Brenchley, J.; Casazza, J.; Koup, R.; Picker, L., Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection, J. Virol., 75, 24, 11983-11991 (2001) |
| [11] | Blankson, J. N.; Gallant, J. E.; Quinn, T. C.; Bartlett, J. G.; Siliciano, R. F., Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients, JAMA, 288, 2, 162-164 (2002) |
| [12] | Bonhoeffer, S.; Rembiszewski, M.; Ortiz, G.; Nixon, D., Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection, AIDS, 14, 15, 2313-2322 (2000) |
| [13] | Brandt, M.; Chen, G., Feedback control of a biodynamical model of HIV-1, IEEE Trans. Biomed. Eng., 48, 7, 754-759 (2001) |
| [14] | Bucy, R.; Kilby, J., Perspectives on inducing efficient immune control of HIV-1 replication—a new goal for HIV therapeutics?, AIDS, 15, Suppl 2, S36-S42 (2001) |
| [15] | Carcelain, G.; Tubiana, R.; Samri, A.; Calvez, V.; Delaugerre, C.; Agut, H.; Katlama, C.; Autran, B., Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection, J. Virol., 75, 1, 234-241 (2001) |
| [16] | Davey, R.; Bhat, N.; Yoder, C.; Chun, T.; Metcalf, J.; Dewar, R.; Natarajan, V.; Lempicki, R.; Adelsberger, J.; Miller, K.; Kovacs, J.; Polis, M.; Walker, R.; Falloon, J.; Masur, H.; Gee, D.; Baseler, M.; Dimitrov, D.; Fauci, A.; Lane, H., HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression, Proc. Natl Acad. Sci. USA, 96, 26, 15109-15114 (1999) |
| [17] | de Souza, F., Modeling the dynamics of HIV-1 and CD4 and CD8 lymphocytes, IEEE Eng. Med. Biol. Mag., 18, 1, 21-24 (1999) |
| [18] | D’Offizi, G.; Montesano, C.; Agrati, C.; Gioia, C.; Amicosante, M.; Topino, S.; Narciso, P.; Pucillo, L.; Ippolito, G.; Poccia, F., Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption, AIDS, 16, 18, 2431-2438 (2002) |
| [19] | Dorman, K.; Kaplan, A.; Lange, K.; Sinsheimer, J., Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1?, J. Acquir. Immune Defic. Syndr., 25, 5, 398-402 (2000) |
| [20] | Douek, D.; Brenchley, J.; Betts, M.; Ambrozak, D.; Hill, B.; Okamoto, Y.; Casazza, J.; Kuruppu, J.; Kunstman, K.; Wolinsky, S.; Grossman, Z.; Dybul, M.; Oxenius, A.; Price, D.; Connors, M.; Koup, R., HIV preferentially infects HIV-specific CD4+ T cells, Nature, 417, 6884, 95-98 (2002) |
| [21] | Dybul, M.; Chun, T.; Yoder, C.; Hidalgo, B.; Belson, M.; Hertogs, K.; Larder, B.; Dewar, R.; Fox, C.; Hallahan, C.; Justement, J.; Migueles, S.; Metcalf, J.; Davey, R.; Daucher, M.; Pandya, P.; Baseler, M.; Ward, D.; Fauci, A., Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters, Proc. Natl Acad. Sci. USA, 98, 26, 15161-15166 (2001) |
| [22] | Fagard, C.; Oxenius, A.; Günthard, H.; Garcia, F.; Braz, M. L.; Mestre, G.; Battegay, M.; Furrer, H.; Vernazza, P.; Bernasconi, E.; Telenti, A.; Weber, R.; Leduc, D.; Yerly, S.; Price, D.; Dawson, S. J.; Klimkait, T.; Perneger, T. V.; McLean, A.; Clotet, B.; Gatell, J. M.; Perrin, L.; Plana, M.; Phillips, R.; Hirschel, B.; Study, S. H.C., A prospective trial of structured treatment interruptions in human immunodeficiency virus infection, Arch. Intern. Med., 163, 10, 1220-1226 (2003) |
| [23] | Finzi, D.; Blankson, J.; Siliciano, J.; Margolick, J.; Chadwick, K.; Pierson, T.; Smith, K.; Lisziewicz, J.; Lori, F.; Flexner, C.; Quinn, T.; Chaisson, R.; Rosenberg, E.; Walker, B.; Gange, S.; Gallant, J.; Siliciano, R., Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy, Nat. Med., 5, 5, 512-517 (1999) |
| [24] | Fischer, M.; Hafner, R.; Schneider, C.; Trkola, A.; Joos, B.; Joller, H.; Hirschel, B.; Weber, R.; Günthard, H. F.; Study, S. H.C., HIV RNA in plasma rebounds within days during structured treatment interruptions, AIDS, 17, 2, 195-199 (2003) |
| [25] | Frost, S., Dynamics and evolution of HIV-1 during structured treatment interruptions, AIDS Rev., 4, 3, 119-127 (2002) |
| [26] | Frost, S.; Martinez-Picado, J.; Ruiz, L.; Clotet, B.; Brown, A., Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection, J. Virol., 76, 3, 968-979 (2002) |
| [27] | Garcia, F.; Plana, M.; Ortiz, G.; Bonhoeffer, S.; Soriano, A.; Vidal, C.; Cruceta, A.; Arnedo, M.; Gil, C.; Pantaleo, G.; Pumarola, T.; Gallart, T.; Nixon, D.; Miró, J.; Gatell, J., The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection, AIDS, 15, 9, F29-F40 (2001) |
| [28] | Gegeny, T., Surviving with HIV in the HAART era: emerging challenges, Res. Initiat. Treat. Action, 6, 3, 12-14 (2000) |
| [29] | Gloster, S.; Newton, P.; Cornforth, D.; Lifson, J.; Williams, I.; Shaw, G.; Borrow, P., Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection, AIDS, 18, 5, 749-755 (2004) |
| [30] | Gray, C.; Lawrence, J.; Ranheim, E.; Vierra, M.; Zupancic, M.; Winters, M.; Altman, J.; Montoya, J.; Zolopa, A.; Schapiro, J.; Haase, A.; Merigan, T., Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells, AIDS Res. Hum. Retroviruses, 16, 14, 1357-1369 (2000) |
| [31] | Grimm, G., Messina, M., Teel, A., Tuna, S., 2003. Model predictive control when a local control lyapunov function is not available. In: Proceedings of the 2003 American Control Conference, vol. 5. pp. 4125-4130. |
| [32] | Gulick, R. M., Structured treatment interruption in patients infected with HIV: a new approach to therapy, Drugs, 62, 2, 245-253 (2002) |
| [33] | Harrer, T.; Harrer, E.; Kalams, S.; Barbosa, P.; Trocha, A.; Johnson, R.; Elbeik, T.; Feinberg, M.; Buchbinder, S.; Walker, B., Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load, J. Immunol., 156, 7, 2616-2623 (1996) |
| [34] | Harrer, T.; Harrer, E.; Kalams, S.; Elbeik, T.; Staprans, S.; Feinberg, M.; Cao, Y.; Ho, D.; Yilma, T.; Caliendo, A.; Johnson, R.; Buchbinder, S.; Walker, B., Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection, AIDS Res. Hum. Retroviruses, 12, 7, 585-592 (1996) |
| [35] | Haslett, P.; Nixon, D.; Shen, Z.; Larsson, M.; Cox, W.; Manandhar, R.; Donahoe, S.; Kaplan, G., Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy, J. Infect. Dis., 181, 4, 1264-1272 (2000) |
| [36] | Hatano, H.; Vogel, S.; Yoder, C.; Metcalf, J.; Dewar, R.; Davey, R.; Polis, M., Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression, AIDS, 14, 10, 1357-1363 (2000) |
| [37] | Havlir, D. V., Structured intermittent treatment for HIV disease: necessary concession or premature compromise?, Proc. Natl Acad. Sci. USA, 99, 1, 4-6 (2002) |
| [38] | Ho, D.; Neumann, A.; Perelson, A.; Chen, W.; Leonard, J.; Markowitz, M., Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature, 373, 6510, 123-126 (1995) |
| [39] | Hoffmann, C., Kamps, B. (Eds.), 2003. HIV Medicine. Flying Publisher. |
| [40] | Jin, X.; Bauer, D.; Tuttleton, S.; Lewin, S.; Gettie, A.; Blanchard, J.; Irwin, C.; Safrit, J.; Mittler, J.; Weinberger, L.; Kostrikis, L.; Zhang, L.; Perelson, A.; Ho, D., Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques, J. Exp. Med., 189, 6, 991-998 (1999) |
| [41] | Kalams, S.; Buchbinder, S.; Rosenberg, E.; Billingsley, J.; Colbert, D.; Jones, N.; Shea, A.; Trocha, A.; Walker, B., Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection, J. Virol., 73, 8, 6715-6720 (1999) |
| [42] | Kalams, S.; Goulder, P.; Shea, A.; Jones, N.; Trocha, A.; Ogg, G.; Walker, B., Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy, J. Virol., 73, 8, 6721-6728 (1999) |
| [43] | Kaufmann, D.; Rosenberg, E., The value of preserving HIV-specific immune responses, J. HIV Ther., 8, 1, 19-25 (2003) |
| [44] | Kaufmann, D., Lichterfeld, M., Altfeld, M., Allen, T., Johnston, M., Lee, P., Wagner, B., Kalife, E., Strick, D., Rosenberg, E., Walker, B.D., 2004. Limited durability of immune control following treated acute hiv infection. In: The 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. |
| [45] | Kellett, C., Teel, A., 2002. On robustness of stability and lyapunov functions for discontinuous difference equations. In: Proceedings of the 41st IEEE Conference on Decision and Control. pp. 4282-4287. |
| [46] | Kirschner, D.; Webb, G., A mathematical model of combined drug therapy of HIV infection, J. Theor. Med., 1, 25-34 (1997) · Zbl 0925.92073 |
| [47] | Koup, R.; Safrit, J.; Cao, Y.; Andrews, C.; McLeod, G.; Borkowsky, W.; Farthing, C.; Ho, D., Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome, J. Virol., 68, 7, 4650-4655 (1994) |
| [48] | Lisziewicz, J.; Rosenberg, E.; Lieberman, J.; Jessen, H.; Lopalco, L.; Siliciano, R.; Walker, B.; Lori, F., Control of HIV despite the discontinuation of antiretroviral therapy, N. Engl. J. Med., 340, 21, 1683-1684 (1999) |
| [49] | Lori, F.; Lisziewicz, J., Structured treatment interruptions for the management of HIV infection, JAMA, 286, 23, 2981-2987 (2001) |
| [50] | Lori, F.; Maserati, R.; Foli, A.; Seminari, E.; Timpone, J.; Lisziewicz, J., Structured treatment interruptions to control HIV-1 infection, Lancet, 355, 9200, 287-288 (2000) |
| [51] | Manegold, C.; Hannoun, C.; Wywiol, A.; Dietrich, M.; Polywka, S.; Chiwakata, C.; Günther, S., Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy, Clin. Infect. Dis., 32, 1, 144-148 (2001) |
| [52] | Martinez-Picado, J.; Morales-Lopetegi, K.; Wrin, T.; Prado, J. G.; Frost, S. D.W.; Petropoulos, C. J.; Clotet, B.; Ruiz, L., Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions, AIDS, 16, 6, 895-899 (2002) |
| [53] | Mayne, D.; Rawlings, J.; Rao, C.; Scokaert, P., Constrained model predictive control: stability and optimality, Automatica, 36, 789-814 (2000) · Zbl 0949.93003 |
| [54] | McMichael, A.; Rowland-Jones, S., Cellular immune responses to HIV, Nature, 410, 6831, 980-987 (2001) |
| [55] | Messina, M., Tuna, S., Teel, A., 2004. Robust stabilization of discrete-time nonlinear systems by certainty equivalence output feedback with applications to model predictive control. In: Proceedings of the 2004 American Control Conference, vol. 3. pp. 2202-2207. |
| [56] | Migueles, S.; Laborico, A.; Shupert, W.; Sabbaghian, M.; Rabin, R.; Hallahan, C.; Baarle, D. V.; Kostense, S.; Miedema, F.; McLaughlin, M.; Ehler, L.; Metcalf, J.; Liu, S.; Connors, M., HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors, Nat. Immunol., 3, 11, 1061-1068 (2002) |
| [57] | Mocroft, A.; Ruiz, L.; Reiss, P.; Ledergerber, B.; Katlama, C.; Lazzarin, A.; Goebel, F.; Phillips, A.; Clotet, B.; Lundgren, J., Virological rebound after suppression on highly active antiretroviral therapy, AIDS, 17, 12, 1741-1751 (2003) |
| [58] | Mollet, L.; Li, T.; Samri, A.; Tournay, C.; Tubiana, R.; Calvez, V.; Debré, P.; Katlama, C.; Autran, B., Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups, J. Immunol., 165, 3, 1692-1704 (2000) |
| [59] | Montaner, L., Structured treatment interruptions to control HIV-1 and limit drug exposure, Trends Immunol., 22, 2, 92-96 (2001) |
| [60] | Moss, R.; Jensen, F.; Carlo, D., Insights into HIV-specific immune function: implications for therapy and prevention in the new millennium, Clin. Immunol., 95, 2, 79-84 (2000) |
| [61] | Neumann, A.; Tubiana, R.; Calvez, V.; Robert, C.; Li, T.; Agut, H.; Autran, B.; Katlama, C., HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group, AIDS, 13, 6, 677-683 (1999) |
| [62] | Ortiz, G.; Nixon, D.; Trkola, A.; Binley, J.; Jin, X.; Bonhoeffer, S.; Kuebler, P.; Donahoe, S.; Demoitie, M.; Kakimoto, W.; Ketas, T.; Clas, B.; Heymann, J.; Zhang, L.; Cao, Y.; Hurley, A.; Moore, J.; Ho, D.; Markowitz, M., HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy, J. Clin. Invest., 104, 6, R13-R18 (1999) |
| [63] | Ortiz, G.; Wellons, M.; Brancato, J.; Vo, H.; Zinn, R.; Clarkson, D.; Loon, K. V.; Bonhoeffer, S.; Miralles, G.; Montefiori, D.; Bartlett, J.; Nixon, D., Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects, Proc. Natl Acad. Sci. USA, 98, 23, 13288-13293 (2001) |
| [64] | Ostrowski, M.; Gu, J.; Kovacs, C.; Freedman, J.; Luscher, M.; MacDonald, K., Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses, J. Infect. Dis., 184, 10, 1268-1278 (2001) |
| [65] | Oxenius, A.; Price, D.; Günthard, H.; Dawson, S.; Fagard, C.; Perrin, L.; Fischer, M.; Weber, R.; Plana, M.; García, F.; Hirschel, B.; McLean, A.; Phillips, R., Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection, Proc. Natl Acad. Sci. USA, 99, 21, 13747-13752 (2002) |
| [66] | Palmer, B.; Boritz, E.; Blyveis, N.; Wilson, C., Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4(+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication, J. Virol., 76, 12, 5925-5936 (2002) |
| [67] | Papasavvas, E.; Ortiz, G.; Gross, R.; Sun, J.; Moore, E.; Heymann, J.; Moonis, M.; Sandberg, J.; Drohan, L.; Gallagher, B.; Shull, J.; Nixon, D.; Kostman, J.; Montaner, L., Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption, J. Infect. Dis., 182, 3, 766-775 (2000) |
| [68] | Papasavvas, E.; Grant, R. M.; Sun, J.; Mackiewicz, A.; Pistilli, M.; Gallo, C.; Kostman, J. R.; Mounzer, K.; Shull, J.; Montaner, L. J., Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients, AIDS, 17, 16, 2337-2343 (2003) |
| [69] | Perelson, A.; Nelson, P., Mathematical analysis of hiv-1 dynamics in vivo, SIAM Rev., 41, 1, 3-44 (1999) · Zbl 1078.92502 |
| [70] | Perelson, A.; Neumann, A.; Markowitz, M.; Leonard, J.; Ho, D., HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, Science, 271, 5255, 1582-1586 (1996) |
| [71] | Phillips, A.; Staszewski, S.; Lampe, F.; Youle, M.; Klauke, S.; Bickel, M.; Sabin, C.; Doerr, H.; Johnson, M.; Loveday, C.; Miller, V., Human immunodeficiency virus rebound after suppression to \(< 400\) copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression, J. Infect. Dis., 186, 8, 1086-1091 (2002) |
| [72] | Pitcher, C.; Quittner, C.; Peterson, D.; Connors, M.; Koup, R.; Maino, V.; Picker, L., HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression, Nat. Med., 5, 5, 518-525 (1999) |
| [73] | Rodes, B.; Toro, C.; Paxinos, E.; Poveda, E.; Martinez-Padial, M.; Benito, J.; Jimenez, V.; Wrin, T.; Bassani, S.; Soriano, V., Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection, AIDS, 18, 8, 1109-1116 (2004) |
| [74] | Rosenberg, E.; Walker, B., HIV type 1-specific helper T cells: a critical host defense, AIDS Res. Hum. Retroviruses, 14, Suppl 2, S143-S147 (1998) |
| [75] | Rosenberg, E.; Billingsley, J.; Caliendo, A.; Boswell, S.; Sax, P.; Kalams, S.; Walker, B., Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia, Science, 278, 5342, 1447-1450 (1997) |
| [76] | Rosenberg, E.; LaRosa, L.; Flynn, T.; Robbins, G.; Walker, B., Characterization of HIV-1-specific T-helper cells in acute and chronic infection, Immunol. Lett., 66, 1-3, 89-93 (1999) |
| [77] | Rosenberg, E.; Altfeld, M.; Poon, S.; Phillips, M.; Wilkes, B.; Eldridge, R.; Robbins, G.; D’Aquila, R.; Goulder, P.; Walker, B., Immune control of HIV-1 after early treatment of acute infection, Nature, 407, 6803, 523-526 (2000) |
| [78] | Ruiz, L.; Martinez-Picado, J.; Romeu, J.; Paredes, R.; Zayat, M.; Marfil, S.; Negredo, E.; Sirera, G.; Tural, C.; Clotet, B., Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression, AIDS, 14, 4, 397-403 (2000) |
| [79] | Ruiz, L.; Carcelain, G.; Martínez-Picado, J.; Frost, S.; Marfil, S.; Paredes, R.; Romeu, J.; Ferrer, E.; Morales-Lopetegi, K.; Autran, B.; Clotet, B., HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection, AIDS, 15, 9, F19-F27 (2001) |
| [80] | Schmitz, J.; Kuroda, M.; Santra, S.; Sasseville, V.; Simon, M.; Lifton, M.; Racz, P.; Tenner-Racz, K.; Dalesandro, M.; Scallon, B.; Ghrayeb, J.; Forman, M.; Montefiori, D.; Rieber, E.; Letvin, N.; Reimann, K., Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes, Science, 283, 5403, 857-860 (1999) |
| [81] | Schweighardt, B.; Ortiz, G. M.; Grant, R. M.; Wellons, M.; Miralles, G. D.; Kostrikis, L. G.; Bartlett, J. A.; Nixon, D. F., Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions, AIDS, 16, 17, 2342-2344 (2002) |
| [82] | Tremblay, C. L.; Hicks, J. L.; Sutton, L.; Giguel, F.; Flynn, T.; Johnston, M.; Sax, P. E.; Walker, B. D.; Hirsch, M. S.; Rosenberg, E. S.; D’Aquila, R. T., Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection, AIDS, 17, 7, 1086-1089 (2003) |
| [83] | Wein, L.; Zenios, S.; Nowak, M., Dynamic multidrug therapies for HIV: a control theoretic approach, J. Theor. Biol., 185, 1, 15-29 (1997) |
| [84] | Wodarz, D., Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance, J. Theor. Biol., 213, 3, 447-459 (2001) |
| [85] | Wodarz, D.; Nowak, M., Specific therapy regimes could lead to long-term immunological control of HIV, Proc. Natl Acad. Sci. USA, 96, 25, 14464-14469 (1999) |
| [86] | Wodarz, D.; Arnaout, R.; Nowak, M.; Lifson, J., Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus, Philos. Trans. R. Soc. Lond. B Biol. Sci., 355, 1400, 1021-1029 (2000) |
| [87] | Yang, O.; Sarkis, P.; Ali, A.; Harlow, J.; Brander, C.; Kalams, S.; Walker, B., Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes, J. Exp. Med., 197, 10, 1365-1375 (2003) |
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.
